Clinical Trial Update: This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months [Phase 2]

View source ↗

Summary

Phase 2 trial in schizophrenia evaluating tolerability and efficacy of BI 409306 over 6 months; the study was terminated and results have been posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• BI 409306

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Schizophrenia | Phase 2 | Status: TERMINATED | Results posted: 2022-04-04